FOIA Number: HHS-FDA-22-0117

FOIA to FDA for Analyses or Assessments Used by FDA During Deliberations Over Aduhelm

February 2, 2022
FOIA request to the U.S. Food and Drug Administration seeking any final analyses or assessments used by FDA during deliberations over the approval of Aduhelm (aducanumab), an Alzheimer's drug produced by Biogen.